Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback